Generic Name
Bumetanide
Brand Names
Bumex, Enbumyst
FDA approval date: February 28, 1983
Classification: Loop Diuretic
Form: Injection, Spray, Tablet
What is Bumex (Bumetanide)?
Bumex tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with Bumex tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
Summary: Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis. Clinical practice guidelines describe sodium restriction ...
Mechanisms of Diuretic Resistance in Heart Failure, Aim 2
Summary: Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
Summary: Randomized double-blind placebo-controlled crossover study design